Trials / Completed
CompletedNCT03339453
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
Comparison of Glucagon Administered by Either the Nasal (LY900018) or Intra-muscular (GlucaGen®) Routes in Adult Patients With Type 1 Diabetes Mellitus During Controlled Insulin-Induced Hypoglycemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus (T1DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nasal Glucagon | Administered nasally |
| DRUG | Intramuscular Glucagon | Administered IM |
Timeline
- Start date
- 2017-11-10
- Primary completion
- 2017-12-17
- Completion
- 2018-01-13
- First posted
- 2017-11-13
- Last updated
- 2019-09-23
- Results posted
- 2019-09-23
Locations
2 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03339453. Inclusion in this directory is not an endorsement.